Format

Send to

Choose Destination
Fertil Steril. 1997 Jul;68(1):138-42.

Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins.

Author information

1
NV Organon, Oss, The Netherlands.

Abstract

OBJECTIVE:

To assess ongoing pregnancy rates (PRs) in IVF after treatment with recombinant FSH (follitropin beta, Puregon; NV Organon, Oss, The Netherlands) as compared with urinary gonadotropins.

DESIGN:

A combined analysis of three prospective, multicenter, randomized, comparative trials.

SETTING:

Twenty-five IVF centers in 13 countries.

PATIENT(S):

Six hundred ninety-seven infertile women receiving recombinant FSH and 463 women receiving hMG or urinary FSH and undergoing one cycle of controlled ovarian hyperstimulation and IVF-ET.

INTERVENTION(S):

A center-based and study-based analysis weighing the treatment differences in individual centers and studies, respectively.

MAIN OUTCOME MEASURES(S):

Pregnancy rate at least 12 weeks after ET per started cycle.

RESULTS(S):

In the center-based analysis, the ongoing PR was 22.9% for recombinant FSH and 17.9% for urinary gonadotropins. The 5.0% treatment difference (95% confidence interval [CI], 0.2% to 9.7%) was significant. When the results of the cryoprogram were included, the treatment difference increased to 6.4% (95% CI, 1.4% to 11.3%). Also in the study-based analysis, significantly higher PRs were seen after follitropin beta treatment.

CONCLUSION(S):

Follitropin beta (Puregon) used for controlled ovarian hyperstimulation in IVF yields significantly higher PRs compared with urinary gonadotropins.

PMID:
9207599
DOI:
10.1016/s0015-0282(97)81490-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center